The country may be one step closer to a vaccine for the coronavirus. Pfizer announced Monday that early data shows promise.

The company says their shots may be 90% effective at preventing COVID-19, putting them on track to apply for emergency-use approval from the FDA later this month.

Dr. Robert Finberg of UMass Medical School says it’s a preliminary analysis by a data safety monitoring board, and it will still be months before the public will be able to get it.

"Pfizer has been clear they want to get all of the relevant safety data done. I think they are looking at at least a couple of months and they are going to continue the study as it is now, and there will be different evaluations when they reach different end points,” said Dr. Finberg.

The company is one of 10 pharmaceutical makers with a COVID-19 vaccine in late-stage trials. More than 44,000 people around the world are participating in the trial.